Skip to main content
MEDS
NASDAQ Trade & Services

DataMeds AI Settles MIPA Litigation, Extinguishes ~$19M Liability for $450K

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Positive
Importance info
8
Price
$4.88
Mkt Cap
$14.727M
52W Low
$0.823
52W High
$75
52W Position info
493% above low
Off High info
93% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

MEDS has more than doubled off its 52-week low of $0.823.

Summary

DataMeds AI settled all MIPA-related litigation for $450,000, repurchasing 364,099 shares and extinguishing approximately $19 million in balance sheet liability.


Key Events · Legal and Risk Events · MEDS

  • MIPA Litigation Settled

    DataMeds AI entered a settlement agreement with Brian Norton, RxERP, Nomad Capital, Strategix Global, and other parties, resolving both the Florida state court action and Delaware Chancery action with prejudice.

  • $19M Liability Extinguished

    The company anticipates extinguishing approximately $19 million in liability from its consolidated balance sheet as a result of the settlement.

  • $450K Total Payment

    DataMeds paid $450,000 total — $350,000 for repurchase of 364,099 shares of common stock and $100,000 for settlement of the MIPA and all other released claims.

  • 364,099 Shares Repurchased

    The company repurchased and extinguished 364,099 shares of common stock from the Selling Holders as part of the agreement.


Analysis · MEDS · Trade & Services

DataMeds AI resolved two lawsuits stemming from its 2023 Membership Interest Purchase Agreement by paying just $450,000 — $350,000 to repurchase 364,099 shares and $100,000 to settle all claims. In exchange, the company expects to remove roughly $19 million in liability from its balance sheet. That is a substantial cleanup for a company that reported a $26.1 million Q2 loss, going concern doubt, and a Nasdaq delisting risk due to stockholders' equity deficiency. The settlement directly addresses the equity deficiency and removes a major legal overhang, though the share repurchase also reduces outstanding shares by 364,099.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MEDS was trading at $4.88 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $14.7M. The 52-week trading range was $0.82 to $75.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MEDS - Latest Insights

MEDS
Nov 16, 2026, 8:42 AM EST
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.7001
Real-time Price: $0.6232 info
Change: -$0.0769 (-11%) info
Market Cap: $2.884M info
MEDS
Nov 16, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.6232 info
Change: -$0.0868 (-12%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7251
Real-time Price: $0.6232 info
Change: -$0.1019 (-14%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7499
Real-time Price: $0.6232 info
Change: -$0.1267 (-17%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 10:20 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8795
Real-time Price: $0.6232 info
Change: -$0.2563 (-29%) info
Market Cap: $2.884M info